Abstract PTU-33 Table 1 shows degree of adherence to the SBP and the prevalence of dysplastic/malignant change

<table>
<thead>
<tr>
<th>Length (cm)</th>
<th>N</th>
<th>Adherence to Seattle protocol (%)</th>
<th>Indefinite for dysplasia (%)</th>
<th>Low-grade dysplasia (%)</th>
<th>High-grade dysplasia (%)</th>
<th>Malignancy (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;3</td>
<td>406</td>
<td>94.44</td>
<td>0.51</td>
<td>0.51</td>
<td>1.52</td>
<td>0</td>
</tr>
<tr>
<td>3 to 8</td>
<td>666</td>
<td>82.92</td>
<td>5.11</td>
<td>5.05</td>
<td>1.49</td>
<td>0.36</td>
</tr>
<tr>
<td>&gt;8</td>
<td>182</td>
<td>76.57</td>
<td>4.80</td>
<td>2.28</td>
<td>4.35</td>
<td>4.59</td>
</tr>
</tbody>
</table>

*All malignancy were adenocarcinoma.

diagnosis of 61; 64 years old for females. Barrett’s length was not recorded in 81 cases and excluded from the final analysis.

Duodenal inspection findings were: Normal - 96.2%; Duodenitis - 3.4%; Duodenal ulcer (clean base) - 0.4%

Conclusions Our audit demonstrates:

- As Barrett’s length increases, the risk of high grade dysplasia and malignancy increases, but conversely, the degree of adherence to the SBP decreases.
- Duodenal inspection rarely identified significant pathology, and the management of the Barrett’s oesophagus superseded the management any duodenal findings.

We conclude that in the absence of new symptoms suggesting duodenal pathology, Barrett’s surveillance should be considered a distinct examination from a diagnostic OGD. The endoscopist should not need to inspect the duodenum, allowing more time to focus on careful oesophageal inspection and strict adherence to the SBP.

REFERENCES

**PTU-34** SMALL BOWEL CAPSULE ENDOSCOPY: A COMPARISON AGAINST EUROPEAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY PERFORMANCE MEASURES

Olivia Etter*, Rukmini Jagdish, Peter Matthews, Emma Johnston, Samuel Pannick. West Midlands University Hospital, London, UK

10.1136/gutjnl-2021-BSG.107

Introduction In 2019, the European Society of Gastrointestinal Endoscopy (ESGE) published its first performance measures for use by small bowel capsule endoscopy (SBCE) services. There is no published data on performance of UK SBCE services against these metrics. We aimed to evaluate the quality of the SBCE service at a district general hospital.

Method A standardised proforma was designed to capture the performance metrics listed by ESGE. Data was collected retrospectively from SBCEs performed between January 2019 and September 2020 at a single hospital site. Data was drawn from the SBCE procedure report, reported by a consultant gastroenterologist, using Miroview software, and from electronic medical records. Discrepancies were resolved by consensus by two reviewers.

Results 50 patients underwent SBCE in the study period; 1 was excluded from the study due to referral error. We included 49 patients, of which 30 were male, with a median age of 62. Our SBCE service met 5/10 of the targets (Table 1). ‘Lesion detection’ was the performance metric met least often (39%), with ‘use of standard terminology’, ‘indication for SBCE’ and ‘capsule retention rate’ being the best met metrics (100%). Data on ‘reading speed’ was not collected.

Conclusion This analysis is the first to compare a UK SBCE service against newly-released ESGE quality improvement criteria, and the first to report patient-level data from any service. We identified areas of good performance and targets for quality improvement. The Miroview application used by the service for recording reports encourages data capture for some of these quality metrics. Others, such as reading speed and adequacy of bowel preparation need to be more actively recorded when the procedure is reported. A proforma has been devised to assist high quality capsule reporting for the future.

The results from this single-centre study support the need for a larger, multi-centre UK study, assessing UK SBCE service quality on a national level.


**PTU-35** ENDOSCOPIC BIPOLAR RADIOFREQUENCY ABLATION FOR TREATING MALIGNANT BILIARY OBSTRUCTION: SYSTEMATIC REVIEW AND META-ANALYSIS

Fiona Beyer, Stephen Rice, Giovani Orzoco-Leal, Madeleine Still, Hannah O’Keefe, Nicole O’Connor, Avile Stoniute, Dawn Craig, Stephen Pereira, Louise Carr, John Leedas. Population Health Sciences Institute, Newcastle Upon Tyne, UK; University College London Institute, London, UK; Newcastle Upon Tyne Teaching Hospitals, Newcastle Upon Tyne, UK

10.1136/gutjnl-2021-BSG.108

Introduction Early evidence suggests using radiofrequency ablation (RFA) as an adjunct to stenting may improve outcomes in patients with malignant biliary obstruction. RFA can be deployed either at the initial stent insertion or to clear tumour ingrowth in a previously placed stent.

Methods To assess the clinical and cost effectiveness and potential risks of RFA for malignant biliary obstruction,